Treatment Overview
Artificial Ovarian Shielding Protocol is an advanced fertility preservation technique designed to protect a woman’s ovaries from radiation or chemotherapy damage during cancer treatment. Unlike surgical relocation (ovarian transposition), this method uses biomedical shielding, hormonal suppression, or protective agents to minimize gonadal exposure to toxic therapies while maintaining ovarian structure and function.
In Korea, reproductive specialists and oncologists work together to create individualized ovarian protection strategies. These combine precise radiation planning, hormone-regulating medications, gonadoprotective agents, and imaging-guided shielding devices. The aim is to safeguard fertility potential while ensuring effective cancer treatment.
Artificial ovarian shielding is part of a broader field called oncofertility, which Korea has developed into a multidisciplinary specialty integrating reproductive endocrinology, radiation oncology, and biomedical engineering.
Purpose & Benefits
The primary purpose of Artificial Ovarian Shielding Protocols is to preserve ovarian function and fertility during and after cancer therapy.
Key benefits include:
- Protection from radiation exposure: Physical or digital shielding minimizes ovarian radiation dose.
- Hormonal suppression: Temporary downregulation of ovarian activity reduces sensitivity to gonadotoxic damage.
- Maintenance of natural hormone production: Preserves estrogen and progesterone levels after treatment.
- Reduced risk of premature ovarian failure (POF): Helps prevent early menopause and infertility.
- Compatibility with other fertility options: Can be combined with egg freezing or ovarian tissue preservation.
- Non-surgical and time-efficient: Allows immediate integration into cancer treatment without delaying therapy.
- Long-term reproductive benefit: Many patients regain normal menstrual function post-treatment.
In Korean oncofertility care, this protocol is often applied alongside other fertility preservation strategies to maximize reproductive safety.
Ideal Candidates
Artificial Ovarian Shielding is suitable for:
- Women undergoing pelvic or abdominal radiotherapy where ovarian exposure is unavoidable.
- Cancer patients receiving high-dose chemotherapy known to be gonadotoxic.
- Young women with curable cancers who wish to preserve natural fertility.
- Patients who cannot delay cancer treatment to undergo egg freezing.
- Individuals for whom surgical transposition is not possible or contraindicated.
- Adolescent patients who are not candidates for oocyte or embryo cryopreservation.
The protocol is often recommended for cancers such as lymphoma, cervical cancer, rectal cancer, and pelvic sarcomas, where radiation fields overlap with ovarian tissue.
Possible Risks & Complications
While the Artificial Ovarian Shielding Protocol is safe and non-invasive, potential risks or limitations include:
- Partial protection: Some radiation scatter or chemotherapy exposure may still affect ovarian tissue.
- Hormonal imbalance: Temporary menopause-like symptoms may occur during hormonal suppression therapy.
- Incomplete efficacy: Fertility may not be fully preserved depending on treatment intensity and patient age.
- Coordination challenges: Requires precise timing between oncology and fertility teams.
- Minor side effects: Possible from hormone-suppressive medications, such as hot flashes or mood changes.
Korean fertility and oncology centers mitigate these risks through real-time imaging, radiation planning software, and hormonal balance monitoring throughout treatment.
Techniques & Protocol Components
The Artificial Ovarian Shielding Protocol combines several methods for optimal ovarian protection. Korean fertility centers use a multi-modal approach customized for each patient’s cancer type, treatment plan, and age.
1. Radiation Shielding
- Physical shielding devices made from lead or advanced biocompatible materials are placed between the radiation field and the ovaries.
- 3D conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) precisely shape radiation beams to avoid ovarian exposure.
- Image-guided radiation therapy (IGRT) further ensures that ovarian tissues remain outside the high-dose field.
2. Pharmacologic Ovarian Suppression
- Gonadotropin-Releasing Hormone (GnRH) agonists or antagonists temporarily suppress ovarian activity, reducing sensitivity to chemotherapy or radiation.
- Commonly administered 1–2 weeks before treatment and continued throughout therapy.
- Reduces the mitotic activity of ovarian follicles, limiting cytotoxic damage.
3. Antioxidant & Protective Agents
- Use of gonadoprotective agents such as melatonin, coenzyme Q10, and antioxidants to reduce oxidative stress on ovarian cells.
- These support follicular survival and maintain ovarian microvascular integrity during exposure.
4. Hormonal Modulation
- Estrogen and progesterone levels are regulated to keep ovaries in a resting, less vulnerable state.
- Prevents premature depletion of the follicular pool during treatment.
5. Thermoplastic and Digital Shielding Systems
- Advanced radiotherapy planning software creates digital ovarian maps to monitor radiation scatter dose.
- Korean centers employ customized 3D-printed shields based on pelvic anatomy for superior protection.
6. Adjunctive Cryopreservation Options
- For added security, oocyte or ovarian tissue freezing can be done before treatment if time permits.
- Provides a backup fertility option in case ovarian function is partially lost.
Recovery & Aftercare
After completion of cancer therapy:
- Hormone function evaluation: Regular blood tests to assess FSH, LH, estradiol, and AMH levels.
- Cycle resumption: Menstrual cycles often return within months post-treatment if ovarian function is preserved.
- Fertility assessment: Ultrasound monitoring to evaluate ovarian reserve and uterine recovery.
- Long-term counseling: Includes reproductive planning and psychosocial support after cancer remission.
- Follow-up fertility care: If ovarian reserve is reduced, patients may transition to IVF or assisted reproduction.
Korean oncofertility programs emphasize comprehensive rehabilitation, including endocrine monitoring, emotional support, and family-building options after recovery.
Results & Effectiveness
Clinical outcomes from artificial ovarian shielding show highly promising results:
- Reduced ovarian radiation dose: Decrease of up to 60–90% depending on technique.
- Preserved hormonal function: Many patients maintain natural menstrual cycles after treatment.
- Fertility retention: 40–70% of women retain ovarian activity post-therapy, depending on age and radiation dose.
- Improved quality of life: Prevents early menopause and maintains endocrine health.
- Compatibility with cancer treatment: Does not compromise the effectiveness of radiotherapy or chemotherapy.
In Korea, the integration of precision imaging, AI-based dose mapping, and advanced GnRH protocols has significantly improved the success rates of ovarian function preservation during cancer therapy.
Treatment Process in Korea
Step 1 – Oncofertility Consultation
- Joint evaluation by oncologists and reproductive endocrinologists.
- Assessment of cancer type, location, treatment schedule, and fertility goals.
Step 2 – Customized Shielding Design
- Radiation oncologists use imaging to plan ovarian position and dose limitation.
- Physical or digital shields designed to minimize exposure.
Step 3 – Hormonal Preparation
- GnRH agonists administered to suppress ovarian function before treatment starts.
- Hormone monitoring ensures suppression efficiency.
Step 4 – Radiation / Chemotherapy with Ovarian Protection
- During therapy, shielding devices and software-guided beam modulation are used.
- Continuous dose monitoring ensures ovarian safety thresholds are maintained.
Step 5 – Post-Treatment Recovery & Fertility Follow-Up
- Hormone recovery and ovarian reserve testing at regular intervals.
- Additional fertility options (IVF, oocyte thawing) offered post-remission if desired.
Why Korea Leads in Artificial Ovarian Shielding
- Integrated Cancer–Fertility Programs: Multidisciplinary collaboration between oncology and reproductive medicine.
- High-Precision Radiotherapy Systems: IMRT, proton therapy, and AI-based radiation mapping minimize ovarian exposure.
- Advanced Pharmacologic Support: Optimized GnRH and hormonal suppression regimens for individual patients.
- Innovative Biomedical Engineering: Use of 3D-printed custom pelvic shields tailored to anatomy.
- Rapid Implementation: Protocols designed to protect fertility without delaying life-saving cancer therapy.
- Holistic Care: Emotional, nutritional, and reproductive counseling included in oncofertility services.
These factors make Korean fertility centers world leaders in ovarian protection during cancer treatment.
Cost Range
The cost of Artificial Ovarian Shielding in Korea varies based on cancer type, shielding technology, and concurrent therapies. Approximate costs include:
- GnRH or hormonal suppression medication: USD 300 – 800 per cycle
- Radiation shielding and dose planning: USD 1,000 – 2,500
- 3D imaging and ovarian mapping: USD 500 – 1,000
- Comprehensive oncofertility package: USD 3,000 – 6,000
If combined with egg or tissue cryopreservation, additional costs apply. Korean hospitals often offer financial counseling and expedited scheduling for cancer patients requiring immediate fertility protection.
Popular Clinics in Korea
- CHA Fertility Center (Seoul, Bundang): Offers advanced oncofertility and ovarian protection programs.
- Maria Fertility Hospital: Specializes in hormonal suppression and fertility preservation for cancer patients.
- MizMedi Women’s Hospital: Equipped with precision radiotherapy integration for fertility protection.
- Hamchoon Women’s Clinic: Focused on reproductive endocrinology and ovarian health preservation.
- Seoul Women’s Hospital: Provides coordinated cancer-fertility care with international patient support.
